Teicoplanin
Teicoplanin structure
|
Common Name | Teicoplanin | ||
|---|---|---|---|---|
| CAS Number | 61036-62-2 | Molecular Weight | 1879.7 | |
| Density | 1.7±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C88H97Cl2N9O33 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
Use of TeicoplaninTeicoplanin is a semisynthetic glycopeptide antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. |
| Name | Telicoplanin |
|---|---|
| Synonym | More Synonyms |
| Description | Teicoplanin is a semisynthetic glycopeptide antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. |
|---|---|
| Related Catalog |
| Density | 1.7±0.1 g/cm3 |
|---|---|
| Molecular Formula | C88H97Cl2N9O33 |
| Molecular Weight | 1879.7 |
| Exact Mass | 1877.5565820 |
| PSA | 662.41000 |
| LogP | 0.40 |
| Index of Refraction | 1.754 |
| InChIKey | BJNLLBUOHPVGFT-CAYRISATSA-N |
| SMILES | CCCCCCCCCC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC2=C3C=C4C=C2OC5=C(C=C(C=C5)[C@H]([C@H]6C(=O)N[C@@H](C7=C(C(=CC(=C7)O)OC8[C@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C9=C(C=CC(=C9)[C@H](C(=O)N6)NC(=O)[C@@H]4NC(=O)[C@@H]1C2=CC(=CC(=C2)OC2=C(C=CC(=C2)[C@H](C(=O)N[C@H](CC2=CC(=C(O3)C=C2)Cl)C(=O)N1)N)O)O)O)C(=O)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)NC(=O)C)Cl)CO)O)O |
| Storage condition | 2-8℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| RIDADR | NONH for all modes of transport |
| RTECS | WY1559000 |
|
Role of extra-cellular fatty acids in vancomycin induced biofilm formation by vancomycin resistant Staphylococcus aureus.
Pak. J. Pharm. Sci. 26(2) , 383-9, (2013) In the present study a vancomycin resistant Staphylococcus aureus (S. aureus) (VRSA) (Labeled as CP2) was isolated from the blood of a post-operative cardiac patient is described. It harbors a plasmid... |
|
|
A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.
Sci. Transl. Med. 7 , 290ra89, (2015) Currently, no approved therapeutics exist to treat or prevent infections induced by Ebola viruses, and recent events have demonstrated an urgent need for rapid discovery of new treatments. Repurposing... |
|
|
Once-weekly dalbavancin versus daily conventional therapy for skin infection.
N. Engl. J. Med. 370(23) , 2169-79, (2014) Dalbavancin, a lipoglycopeptide antibiotic agent that is active against gram-positive pathogens, has a long plasma half-life, allowing for once-weekly dosing. DISCOVER 1 and DISCOVER 2 were identicall... |
| teichomycin |
| TEICOPLANIN |
| (1S,2R,19R,22R,34S,37R,40R,52R)-2-[(2-Acetamido-2-deoxy-β-D-glucopyranosyl)oxy]-22-amino-5,15-dichloro-64-{[2-(decanoylamino)-2-deoxy-β-D-glucopyranosyl]oxy}-26,31,44,49-tetrahydroxy-47-(α-D -mannopyranosyloxy)-21,35,38,54,56,59-hexaoxo-7,13,28-trioxa-20,36,39,53,55,58-hexaazaundecacyclo[38.14.2.2.2.2.1.1.1.1.0.0]hexahexaconta-3,
 5,8(64),9,11,14,16,23(61),24,26,29(60),30,32 |
| TEICOPLANIN,JP |
| Tagocid |
| TeicoplaninSodium |
| 8327a |
| TEIC |
| Teicoplanin(sterile,non-sterile) |
| antibiotic8327a |
| Teocoplanin |